Type 2 Diabetes Mellitus
Conditions
Interventions
Case Series:Canagliflozin
Sponsors
Beijing Luhe Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The main criteria for inclusion were as follows: 1. Participants were diagonsed with type 2 diabeteswith hyperuricemia (serum uric acid =420µmol/l); 2. Participants were new-onset diabetes or treated with stable oral anti-diabetic agents for at least 8 weeks; 3. The glycated hemoglobin level of the patients were at the range of 7.0% and =10.5%; 4. The participants were 18-75 years old; 5. The participants could understand the procedure of the study and promise to finish the trail, and sign the informed consent; 6. The participants promise to keep the same life habit and take the medicine on time.
Exclusion criteria
Exclusion criteria: 1. Known allergies, hypersensitivity, or intolerance to canagliflozin or its excipients; 2. Current use of, or likely to require treatment with, a corticosteroid medication within 6 months; 3. Participants involvement in other studies within 3 months; 4. History of drug or alcohol abuse within 3 years before screening; 5. History of gout attacks or kidney stone attacks; 6. Myocardial enzyme level >3.0 times; 7. Increased serum amylase and lipase level; 8. ALT levels >2.0 times the ULN or total bilirubin >1.5 times the ULN, at screening; 9. Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 at screening; 10. History of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy; 11. Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident within 3 months before screening; 12. Arrhymia need to be treated; 13. History of major surgery (ie, requiring general anesthesia) within 3 months of the screening visit; 14. History of malignancy within 5 years before screening; 15. History of HIV antibody positive; 16. The expected lifespan less than 1 yeas; 17. urinary infection at screen; 18. History of arterial occlusion of lower extremity; 19. Pregnant or breast-feeding or planning to become pregnant or breast-feed during the study; 20. The participants were thought to be allergic or intolerance to the agent by the researcher; 21. History of diabetic foot.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid;Glycosylated hemoglobin; | — |
Countries
China
Contacts
Public ContactDong Zhao
Beijing Luhe Hospital, Capital Medical University
Outcome results
None listed